Targeting G3BP1 Condensate Topology Promotes Stress Granule Assembly via m <sup>6</sup> A‐IGF2BP1 for Ischemic Stroke Rescue
Ras-GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) mediates stress granules (SGs) via phase separation. However, there is limited understanding of the allosteric mechanism and the identification of regulatory molecules. Here, we identify icariin (ICA), a small-molecule inducer that promotes G3BP1-driven biomolecular condensate formation, which effectively restructures SGs architecture. Moreover, we demonstrate that ICA interacts with the N-terminal nuclear transport factor 2-like (NTF2L) domain of G3BP1, inducing a conformational switch from "closed-to-open" that facilitates G3BP1 oligomerization and phase separation. Crucially, G3BP1 condensates recruit N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) reader insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) through topology-selective scaffolding, establishing epitranscriptomic hubs that resolve proteotoxic stress via m<sup>6</sup>A-dependent AMP-activated protein kinase (AMPK)-mitogen-activated protein kinase (MAPK)-glutathione peroxidase 4 (GPX4) signaling pathways. Strikingly, this chemical intervention shows translational potential, as ICA reduces cerebral infarct volume in ischemia models via G3BP1-dependent SGs remodeling. Additionally, single-nucleus transcriptomics identify Fezf2, Pou3f1, and Kcnn2 neuronal subpopulations as mechanistically aligned responders. Furthermore, ischemic stroke patients reveal G3BP1-IGF2BP1-m<sup>6</sup>A axis within peripheral blood mononuclear cells. Taken together, this study redefines SGs as dynamically druggable epitranscriptomic processors for precision neuroprotection. In particular, a framework for leveraging biomolecular condensate topology in the development of next-generation neurological therapeutics is offered.
Authors
- Pengfei Tu (ORCID: https://orcid.org/0000-0003-3553-1840)
- Fang‐Fang Zhuo
- Bo Han (ORCID: https://orcid.org/0000-0002-6509-0313)
- Qian‐Wei Luo
- Ke‐Wu Zeng (ORCID: https://orcid.org/0000-0003-1082-6327)
- Yan Guo (ORCID: https://orcid.org/0000-0003-3309-865X)
- Peipei Zhang (ORCID: https://orcid.org/0000-0003-1742-1680)
- Xiaowen Zhang (ORCID: https://orcid.org/0000-0002-0072-2439)
- Yi Wang (ORCID: https://orcid.org/0000-0001-9921-0304)
- Ling Li (ORCID: https://orcid.org/0000-0002-1160-8914)
- Zhuo Yang (ORCID: https://orcid.org/0000-0002-5296-8596)
- Zhiyong Du
- Zhiyuan Lu (ORCID: https://orcid.org/0000-0001-6840-7227)
- Zhengping Liu (ORCID: https://orcid.org/0000-0002-7944-2455)
- Wei Zhou (ORCID: https://orcid.org/0000-0002-4856-4919)
- Can Zheng (ORCID: https://orcid.org/0000-0002-3752-8314)
- Tai Wei (ORCID: https://orcid.org/0000-0002-9629-0158)
- Wei Yu (ORCID: https://orcid.org/0000-0002-9672-3849)
Institutions
- Shihezi University (CN)
- China Pharmaceutical University (CN)
- Peking University (CN)
- Beijing Anzhen Hospital (CN)
- Shandong Academy of Pharmaceutical Sciences (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1002/advs.202514703
- Citations
- 1
- Primary Topic
- RNA Research and Splicing
- Type
- article
- Field-Weighted Citation Impact
- 0.81